Vor Biopharma Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual report, not a standalone fourth-quarter earnings report. Vor is a clinical-stage cell and genome engineering company focused on blood cancers; it has no approved products and has generated no product revenue.
Key financial metrics
| Metric | FY2021 / Dec. 31, 2021 | FY2020 / Dec. 31, 2020 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $47.5 million | $31.6 million |
| General and administrative expense | $21.5 million | $11.7 million |
| Total operating expenses | $69.0 million | $43.4 million |
| Net loss | $68.9 million | $43.3 million |
| Net loss attributable to common stockholders per share | $2.10 | $230.57 |
| Cash used in operating activities | $69.1 million | $36.3 million |
| Cash, cash equivalents and investments | $207.5 million | $48.5 million cash and cash equivalents; no investments |
Margins: Not meaningful because the company had no product revenue. Interest income was $0.1 million in 2021. The per-share loss comparison is not directly informative: the 2020 weighted-average share count was much lower, and Vor completed its IPO and converted preferred stock in 2021.
At year-end, total assets were $242.6 million and total liabilities were $26.3 million, including $18.0 million of recorded operating lease liabilities. The filing reports no financial debt balance. Current assets were $214.4 million and current liabilities were $10.2 million. Cash flow from investing was a $91.7 million outflow, mainly purchases of investments; financing provided $232.9 million, primarily from preferred-stock financing and the IPO.
Material changes versus FY2020
- Net loss increased by $25.6 million as total operating expenses rose by $25.7 million. R&D expense increased $15.9 million, mainly from higher personnel, clinical and preclinical activity, and facilities costs.
- G&A expense increased $9.7 million, reflecting higher headcount, professional fees, insurance and facilities costs.
- Operating cash use increased $32.9 million. The company also invested $87.8 million in marketable securities during 2021.
- Vor raised approximately $186.3 million in net IPO proceeds in February 2021 and received $45.4 million from a preferred-stock financing. All outstanding preferred stock converted to common stock at the IPO.
Business, outlook and principal risks
- Lead program: VOR33, an engineered hematopoietic stem-cell transplant intended to remove CD33 from healthy cells, is being studied with Mylotarg in the Phase 1/2a VBP101 trial for high-relapse-risk CD33-positive AML. The trial’s main objectives are tolerability, feasibility and engraftment—not demonstrating efficacy. Initial data were anticipated in the second half of 2022.
- Other programs: VCAR33 AUTO is in an investigator-sponsored Phase 1/2 trial; timing of initial data expected in 2022 depends on the investigator. Vor planned to submit an IND for VCAR33 ALLO in the first half of 2023. The proposed VOR33 + VCAR33 Treatment System would be developed after initial data from the relevant programs.
- Liquidity outlook: Management estimated year-end cash, cash equivalents and investments would fund operating expenses and capital needs into the fourth quarter of 2023. The estimate depends on assumptions and the company expects to need additional capital. The filing describes a planned $350 million shelf registration and a proposed at-the-market offering of up to $125 million, both subject to effectiveness of the shelf registration statement.
- Operating plans: Vor was building an in-house clinical manufacturing facility in Cambridge and expected it to be operational in 2022. Expanded leased space adds future commitments; the filing lists $26.4 million of lease payments and separately excludes $30.1 million associated with amendments for space not yet commenced at year-end.
- Key risks: substantial ongoing losses and future financing needs; unvalidated engineered-cell and genome-editing approaches; clinical, safety and regulatory uncertainty; manufacturing and third-party supply dependence; reliance on licensed intellectual property; competition; and potential reimbursement challenges. COVID-19 had delayed VOR33 site activation and enrollment, and could further disrupt trials, suppliers and operations.
- Contingencies and controls: Vor reported no material legal proceedings. Management concluded disclosure controls and internal control over financial reporting were effective at December 31, 2021. The independent auditor gave an unqualified opinion on the financial statements but did not audit internal control effectiveness.
Investor facts to verify
- Actual VBP101 progress and results, especially VOR33 engraftment, safety and any evidence of protection from Mylotarg-related myelosuppression.
- Cash burn, financing activity and runway relative to the company’s stated fourth-quarter 2023 estimate; confirm the status and terms of the proposed shelf and ATM offerings.
- Whether the Cambridge manufacturing facility became operational as planned and whether clinical supply, quality and scale-up requirements are being met.
- Progress toward the VCAR33 ALLO IND and the proposed combination program, including regulatory feedback and dependence on third-party trial data, supply and licenses.